Indications -- Cancer Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Indications -- Cancer

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Icebrg who wrote (382)	5/29/2003 5:40:31 AM
From: Icebrg	Read Replies (2) of 1840

Iressa Approved for Non-Small Cell Lung Cancer: An Expert Interview With Alan B. Sandler, MD Laurie Barclay, MD May 27, 2003 — Editor's Note: On May 5, the U.S. Food and Drug Administration (FDA) approved AstraZeneca's gefitinib (Iressa) for non-small cell lung cancer that has progressed despite treatment with platinum-based and docetaxel chemotherapy. Although epidermal growth factor receptor inhibitors like gefitinib are supposed to be more selective for the tumor and hence less toxic, postmarketing surveillance data found about a 2% incidence of interstitial lung disease (ILD) in patients who took it in Japan, where it was first marketed in July 2002, and the Japanese health ministry reported 246 deaths. The ILD rate was much lower in a larger group of US patients who took the drug under an expanded access program. US experts say the specific nature of the ILD link, especially in Japan, remains unclear and will be better defined in further studies. Meantime, they say, gefitinib is an important new tool in refractory lung cancer treatment..... medscape.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next